Immunogenic composition

US11654190B2 · kind B2 · utility

Assignee

• GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

• Amirreza Faridmoayer · Schlieren, CH
• Rainer Follador · Schlieren, CH
• Stefan Jochen KEMMLER · Schlieren, CH
• Michael Kowarik · Bellinzona, CH
• Gerd Martin LIPOWSKY · Bellinzona, CH
• Gerald Johann POSCH · Schlieren, CH
• Fabio SERVENTI · Schlieren, CH

Key dates

• Filing date: Jul 17, 2018
• Grant date: May 23, 2023
• Expiry date: Jul 17, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1→2)]-[Gro-(2→P→3)]-β-D-Galp-(1→4)]-β-L-Rhap-(1→. Also provided are conjugates comprising a →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1→2)]-[Gro-(2→P→3)]-β-D-Galp-(1→4)]-β-L-Rhap-(1→, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.